To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .

NCT06168383 | Completed Phase 2

• 1 other identifier: HSK31679-202
• Study Type: interventional
• Target: 186
• Locations: 1 country
• Sites: 1

Brief Summary

A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.

Conditions

Non-Alcoholic Steatohepatitis (NASH)

Outcome Measures

Primary Outcomes (1)

• Proportions of patients(HSK31679-treated versus placebo-treated) with NASH improvement and with no worsening of fibrosis at week 52 compared with Baseline.

  Improvement of NASH is defined as a 2-point reduction in NAS with at least 1-point reduction in ballooning and no increase in steatosis.

  from Baseline to 52 weeks

Secondary Outcomes (5)

• Proportions of patients(HSK31679-treated versus placebo-treated) with improvement in liver fibrosis greater than or equal to one stage and no worsening of NASH at week 52 compared with Baseline.

  from Baseline to 52 weeks

• Proportions of patients(HSK31679-treated versus placebo-treated) with both improvement of NASH and fibrosis at week 52 compared with Baseline.

  from Baseline to 52 weeks

• The percent relative change from baseline in hepatic fat fraction by MRI-PDFF at 12, 24, 36 and 52 weeks for HSK31679 versus placebo.

  from Baseline to 12, 24, 36, and 52 weeks

• The proportions of patients with 30% or more relative hepatic fat reduction at 12 , 24 , 36 and 52 weeks for HSK31679 versus placebo.

  from Baseline to 12, 24, 36, and 52 weeks

• Assess the effect of HSK31679 compared to placebo on Parameters of blood lipids measured by percent change from Baseline to 12, 24, 36, and 52 weeks.

  from Baseline to 12, 24, 36, and 52 weeks

Study Arms (3)

Double-blind 80 mg Daily

EXPERIMENTAL

Patients take double-blind HSK31679 80 mg for 52 weeks

Drug: HSK31679 80mg

Double-blind 160 mg Daily

EXPERIMENTAL

Patients take double-blind HSK31679 160 mg for 52 weeks

Drug: HSK31679 160mg

Placebo

PLACEBO COMPARATOR

Patients take double-blind placebo for 52 weeks

Drug: Placebo

Interventions

HSK31679 80mg DRUG

once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.

Double-blind 80 mg Daily

HSK31679 160mg DRUG

once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.

Double-blind 160 mg Daily

Placebo DRUG

once daily, oral administration of placebo from Day 1 to Week 52.

Placebo

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must be willing to participate in the study and provide written informed consent.
• Male or female aged 18 ≤ age \< 75 at the time of signing the informed consent
• Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 2 to 3 and a NAS of ≥4 with at least a score of 1 in each of the lobular inflammation and ballooning degeneration.
• Must have confirmation of ≥8% liver fat content on MRI-PDFF.
• Weight changes≤5% in the 6 weeks prior to randomization.If a historical biopsy is to be used, patients must have had weight changed≤5%, too.

You may not qualify if:

• History or presence of cirrhosis，hepatic decompensation or impairment defined as presence of any of the following: history of esophageal varices, ascites, or hepatic encephalopathy, or hepatocellular carcinoma.
• Use of high dose vitamin E (\>400 IU/day)，polyunsaturated fatty acid or ursodeoxycholic acid unless stable for ≥6 months prior to an eligible screening liver biopsy. Use of thiazolidinediones, sodium-glucose co-transporter 2 inhibitors or a complex oral anti-diabetic (OAD) regimen (3 or more OADs) unless stable for ≥3 months prior to an eligible screening liver biopsy.
• Use of Glucagon-like peptide 1 \[GLP-1\] agonist therapy (e.g.,liraglutide, semaglutide, dulaglutide and exenatide ) within 6 months prior to an eligible screening liver biopsy.
• Use of drugs that have the potential to affect thyroid hormone production and/or interfere with thyroid function.
• Potent inhibitors of CYP2C8 such as gemfibrozil and trimethoprim are prohibited. An inducer of CYP2C8, rifampicin, is prohibited.
• Use of drugs historically associated with NAFLD/NASH for 2 weeks prior to an eligible screening liver biopsy, which include, but are not limited, to the following: total parenteral nutritionamiodarone, methotrexate, systemic glucocorticoids (if use within 3 months prior to a biopsy is also not permitted), tamoxifen, tetracycline, estrogens at doses greater than those used for hormone replacement or contraception, anabolic steroids , valproic acid, and known hepatotoxins.
• Regular use of drugs historically associated with NAFLD/NASH within 12 months prior to liver biopsy (including historical biopsy), which include, but are not limited, to the following:PPAR agonists (e.g. lanifibranor, Siglitazone sodium) ，FXR agonists (e.g., obecholic acid, HTD1801)，FGF21 analogs (e.g., AP025, efruxifermin , pegozafermin(B1089-1001)) ; DGAT2 inhibitors (e.g., PF 6865571 and ION224),PDE inhibitors (e.g., ZSP1601) and other thyroid hormone receptor B agonists \[e.g.,resmetirom（MGL-3196）、ASC41 and VK2809).
• Lipid-lowering therapy that did not meet the following criteria: fenofibrate, ezetimibe stable for at least 3 months before randomization and remained unchanged during study treatment, and statins stable for at least 4 weeks before randomization and remained unchanged during study treatment.
• Type 1 diabetes or uncontrolled Type 2 diabetes defined as:
• Hemoglobin A1c \>9.5% at screening (patients with HbA1c \>9.5% may be rescreened),
• Insulin dose adjustment \>20% within 60 days prior to enrollment,
• Requirement for glucagon-like peptide analogue (unless on a stable dose ≥ 6 months prior to screening) or History of severe hypoglycemia (symptomatic hypoglycemia requiring outside assistance to regain normal neurologic status).
• Uncontrolled hypertension (either treated or untreated) defined as systolic blood pressure \>160 mmHg or a diastolic blood pressure \>100 mmHg at screening.
• Evidence of other forms of chronic liver disease including the following:biliary bypass, drug induced liver disease, alcoholic liver disease, autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), hemohemosis, Wilson's disease, α-1 antitrypsin deficiency, bile duct obstruction, primary or metastatic liver cancer, hepatitis B, or present Hepatitis virus (HCV) infection.
• Thyroid diseases: hyperthyroidism and hypothyroidism. Thyroid peroxidase antibodies (TPOAb) or thyroglobulin antibodies (TGAb) that have been determined by the investigators to be clinically significant.

Sponsors & Collaborators

• Haisco Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

Beijing Tsinghua Changgung Hospital, Tsinghua University

Beijing, China

Location

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty Liver; Liver Diseases; Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2023
• First Posted: December 13, 2023
• Study Start: January 5, 2024
• Primary Completion: December 12, 2025
• Study Completion: January 16, 2026
• Last Updated: June 23, 2026

Record last verified: 2026-06

Locations

CN (1)